Insider Trading March 23, 2026

Butler National Director Adds 1,000 Shares as Stock Shows Strong One-Year Gain

Small insider buy accompanies mixed valuation signals: low P/E versus InvestingPro fair-value caution

By Leila Farooq BUKS
Butler National Director Adds 1,000 Shares as Stock Shows Strong One-Year Gain
BUKS

A director of Butler National Corp purchased 1,000 common shares on March 20, 2026, at $3.88 apiece, a $3,880 investment. The transaction occurs amid a 120% one-year gain for the stock and valuation metrics that present conflicting signals: a P/E of 12.84 and InvestingPro commentary that the stock is both trading at a low P/E relative to near-term earnings growth and overvalued versus its calculated Fair Value.

Key Points

  • Director Daly Joseph Patrick purchased 1,000 Butler National (BUKS) shares on March 20, 2026 at $3.88 each, totaling $3,880.
  • BUKS has delivered a 120% return over the past year and is trading at a P/E ratio of 12.84; InvestingPro notes the P/E is low relative to near-term earnings growth.
  • After the transaction, Daly directly owns 4,500,000 shares and indirectly owns 4,360,000 shares through EssigPR, Inc.; InvestingPro flags the stock as overvalued relative to its Fair Value while assigning a "GREAT" financial health score.

On March 20, 2026, director Daly Joseph Patrick reported acquiring 1,000 shares of Butler National Corp common stock at $3.88 per share, for a total outlay of $3,880. The purchase was disclosed under the company ticker BUKS on the NASDAQ.

This transaction comes as Butler National has produced a notable 120% return over the past 12 months. At the time of the filing, the shares were trading at a price-to-earnings ratio of 12.84. An InvestingPro note cited alongside the disclosure highlights that the stock appears to trade at a low P/E relative to near-term earnings growth.

Following the latest purchase, Daly's direct holdings in the company amount to 4,500,000 shares. He also holds an indirect stake of 4,360,000 shares through EssigPR, Inc., according to the filing information.

Valuation commentary attached to the transaction presents mixed signals. While InvestingPro's analysis flags the stock as overvalued relative to its Fair Value estimate, the same platform assigns the company a "GREAT" financial health score. Readers are informed that additional proprietary insights are available through InvestingPro, including 10 further ProTips and a detailed Pro Research Report on BUKS.


Context and takeaways

  • The insider purchase was modest in dollar terms at $3,880, but adds to Daly Joseph Patrick's larger direct and indirect holdings in the company.
  • BUKS has recorded a 120% return over the past year and trades at a P/E of 12.84, which InvestingPro describes as low relative to near-term earnings growth.
  • Despite the low P/E signal, InvestingPro's Fair Value analysis suggests the shares are currently overvalued, even as the company is scored as having "GREAT" financial health.

The filing provides concrete ownership data and highlights contrasting valuation assessments available to investors. For those seeking the deeper model-level valuation work and additional ProTips referenced, the InvestingPro Pro Research Report on Butler National is cited as the source for expanded analysis and tools.

Risks

  • Conflicting valuation signals: InvestingPro notes both a low P/E relative to near-term earnings growth and that the stock is overvalued versus its Fair Value, creating uncertainty for valuation-driven decisions.
  • Concentrated insider holdings: Daly's large direct and indirect positions (4,500,000 and 4,360,000 shares, respectively) may affect shareholder dynamics and liquidity for existing public holders.
  • Reliance on proprietary analysis: The coverage cited references InvestingPro ProTips and a Pro Research Report for further insight, indicating that conclusions may depend on model assumptions and proprietary valuation methods.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026